China approves Everest and Kezar lupus drug trial

SHANGHAI, China - Everest Medicines and Kezar Life Sciences (NASDAQ:KZR), Inc. have received approval from the Center for Drug Evaluation (CDE) of China\'s National Medical Products Administration (NMPA) to initiate a Phase 2b clinical trial for zetomipzomib, a treatment for lupus nephritis (LN), in China. The trial, named PALIZADE, will assess the efficacy and safety...

Read More

Walt Disney Studios names Greenbaum as president

By Dawn Chmielewski and Lisa Richwine (Reuters) - David Greenbaum has been named to the newly created role of president, overseeing Disney Live Action and 20th Century studios, reporting to Disney Entertainment co-Chairman Alan Bergman, Walt Disney (NYSE:DIS) Studios announced on Monday. He succeeds Sean Bailey, who oversaw Disney\'s live action films since 2010, and...

Read More

American Electric Power reports earnings miss, names interim CEO

(Reuters) - Utility firm American Electric Power (NASDAQ:AEP) on Monday reported fourth-quarter earnings that missed analysts\' expectations and named board member Benjamin Fowke as interim chief executive officer, effective immediately. Fowke, the former CEO of peer Xcel Energy (NASDAQ:XEL), will replace Julie Sloat, who had been American Electric\'s chief since January 2023. The change comes...

Read More

Spirit AeroSystems appoints new board member

WICHITA, Kan. - Spirit AeroSystems (NYSE:SPR) Holdings, Inc. [NYSE: SPR], a prominent manufacturer of aerostructures, announced the appointment of Jane P. Chappell to its Board of Directors, effective immediately. Chappell, who brings over four decades of experience in the defense industry, will contribute to the Corporate Governance and Nominating Committee and the Risk Committee. Chappell\'s...

Read More